Gerresheimer’s Audit Drama Intensifies: AGM Scrapped, Stock Retreats, and a New Tech Pact Offers a Glimmer

Gerresheimer cancels annual meeting after audit delay; stock sheds 9%, trades below 200-day MA. BaFin probes leasing and impairments; creditors extend report deadline to 2026.

The annual shareholder meeting scheduled for 3 June has been called off at Gerresheimer – a direct consequence of the missing audited accounts for 2025. Management has promised to set a new date once the audit is complete, but for now the absence of a certified report leaves investors navigating in fog. The decision underscores how deeply the accounting crisis has disrupted the pharmaceutical packaging specialist’s corporate calendar.

That uncertainty has already taken a toll on the share price. After a blistering 60% surge in just one month, the stock shed nearly nine percent last week, closing at €24.92. The retreat pushed the shares approximately nine percent below the 200-day moving average of €27.37, a technical threshold that had capped the rally and now signals a pause in the fragile recovery attempt. From the February nadir of €15.57, the stock had nearly doubled before hitting that wall.

On a broader timeframe, the picture remains bleak. Gerresheimer has lost 60% of its value over the past twelve months and sits more than 61% below its 52-week high of €64.40. The relative strength index has dropped to 28, territory that often precedes a technical bounce, but such a move would lack fundamental backing until the accounting fog clears.

The root of the turmoil extends well beyond chart patterns. Germany’s financial regulator BaFin has been probing Gerresheimer’s interim accounts since March, focusing on leasing liabilities, capitalised development costs, and a €196.5 million impairment in the Advanced Technologies segment. Separately, the audit oversight body APAS is investigating KPMG, the firm that signed off on the 2024 financials without qualifications, amid questions over €35 million in bill-and-hold transactions. An independent review has already confirmed systematic breaches of IFRS rules.

Creditors have responded pragmatically: the deadline for the audited 2025 annual report has been pushed back to the end of September 2026, and leverage covenants are suspended until the close of the third quarter. Management, however, is aiming to deliver the certified report in June – two months ahead of that extended deadline. If successful, that would clear the way for the first-quarter earnings release and, later, the half-year report due on 14 July.

Despite the financial turbulence, the company is not standing still operationally. At the Interpack trade fair in Düsseldorf, Gerresheimer showcased a concrete result of its new partnership with US chemicals group Milliken. The collaboration uses a specialised additive technology that improves the moisture barrier in plastic packaging by up to 40%. Such innovations highlight the underlying technological strength, but market attention remains fixed on the balance sheet.

The planned sale of US subsidiary Centor, a manufacturer of packaging systems for prescription drugs, is intended to provide relief. The division carries a book value of €292 million, and Morgan Stanley has been mandated to run the auction. Interest has already proven double-digit, and a deal is expected to close in 2026. Proceeds would strengthen the company’s hand in negotiations with banks and Schuldschein lenders, as the Bormioli acquisition continues to digest cash. Alongside the disposal, the Chicago Heights plant will be shuttered by the end of fiscal 2026, with production shifting to facilities in Italy and India.

Management has held firm on its operational targets for 2026, forecasting revenue between €2.3 billion and €2.4 billion and an adjusted EBITDA margin of 18% to 19%. That guidance, however, rests on a foundation that has yet to pass independent scrutiny.

Short sellers have taken note: roughly 11% of the free float is currently sold short, leaving the stock acutely sensitive to any fresh news. The next critical waypoint is the June audit opinion. If it arrives clean, the bulls may have reason to return. If not, the fragility evident in this month’s retreat could deepen further.